Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VNDA
Strong SellSinkerVanda Pharmaceuticals Inc. · Healthcare · United States · $320M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Vanda Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Its competitive moat is built upon its proprietary, approved products like Hetlioz for non-24-hour sleep-wake disorder and Fanapt for schizophrenia, addressing significant unmet medical needs in niche patient populations. Vanda maintains a focused R&D pipeline aimed at expanding its CNS franchise.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 254.4M | 192.6M | 198.8M | 216.1M | -5.3% | 215.7M | 248.7M | 337.0M | 24.9% |
| EPS | 0.11 | 0.04 | -0.33 | -3.74 | -63.6% | -4.64 | -3.02 | -1.03 | — |
| Shares | 56.8M | 57.5M | 58.3M | 59.1M | +4.1% | 60.5M | — | — | — |
| Debt | 11.1M | 9.4M | 12.4M | 12.6M | 4.2% | 22.8M | — | — | — |
| Equity | 527.2M | 544.9M | 538.5M | 327.2M | -14.7% | — | — | — | — |
| Op CF | 32.0M | 12.8M | -15.8M | -109.4M | -60.0% | -142.3M | — | — | — |
| Inv CF | 49.9M | -12.1M | -17.4M | 94.9M | — | — | — | — | — |
| Fin CF | 0.7M | 0 | -0.2M | -2.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VNDA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals Inc.(you) | $320M | 18 | Strong Sell |
| IMRX | Immuneering Corporation | $323M | 19 | Strong Sell |
| OBIO | Orchestra BioMed Holdings, Inc. | $312M | 19 | Strong Sell |
| FULC | Fulcrum Therapeutics, Inc. | $294M | 17 | Strong Sell |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $360M | 17 | Strong Sell |
| ALXO | ALX Oncology Holdings Inc. | $277M | 17 | Strong Sell |
| IPSC | Century Therapeutics, Inc. | $367M | 17 | Strong Sell |
| DMAC | DiaMedica Therapeutics Inc. | $345M | 16 | Strong Sell |
| MGNX | MacroGenics, Inc. | $263M | 17 | Strong Sell |
| FATE | Fate Therapeutics, Inc. | $291M | 21 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%